Introduction {#Sec1}
============

Currently, catheter ablation in patients with paroxysmal atrial fibrillation (AF) in which the pulmonary veins (PVs) are electrically isolated is a well-accepted treatment and has proven to be successful \[[@CR1]--[@CR3]\]. However, the efficacy of PV isolation (PVI) alone in long-standing persistent AF (LSP-AF) is poor \[[@CR4]\]. Whereas the single procedure drug-free success rate of PVI in paroxysmal AF ranges between 57 and 80 % \[[@CR5]--[@CR8]\], in contrast PVI in LSP-AF offers rather low success rates (21--22 %) \[[@CR9]--[@CR11]\]. Additional ablation lines and other techniques have been proposed to increase the success rate of LSP-AF ablation, one of these being atrial defragmentation \[[@CR12]\]. During this procedure electrogram-based ablation is performed. Treatment targeting specific areas in the atrial substrate, showing complex fractionated atrial electrograms (CFAEs), has also been proposed \[[@CR13]\]. Although successful termination of AF by using this technique alone has been reported, others have not replicated the encouraging results of this study \[[@CR14]\]. The benefit of PVI and additional linear ablation in the treatment of LSP-AF has been shown in several studies \[[@CR4], [@CR12], [@CR15]\]. It remains unclear if a combination of PVI and CFAE ablation significantly increases the success rate of LSP-AF ablation as opposed to PVI and linear ablation \[[@CR4], [@CR16]\].

The aim of this study was to assess whether complete defragmentation is a useful additional technique in order to achieve a satisfactory clinical outcome in the treatment of LSP-AF.

Methods {#Sec2}
=======

This study was a retrospective data analysis. Data from 37 consecutive patients (age 60.4 ± 7.3 years; 28 male) diagnosed with LSP-AF were compared. Before all procedures a transoesophageal echo was performed to exclude left atrial (LA) thrombus. Twenty-six patients underwent radiofrequency catheter ablation for AF at the Erasmus Medical Center in Rotterdam, the Netherlands, and 11 patients were treated at the Onze Lieve Vrouwe Gasthuis in Amsterdam, the Netherlands. However, the same team of electrophysiologists performed all the procedures at two different locations using identical equipment and procedure strategies. During the procedure, activated clotting time (ACT) levels were monitored and were required to be between 275 and 350 s. Patients were divided into two groups: LA ablation (PVI and linear ablation) with and without defragmentation. Data on outcome and post-procedural complications were collected. The primary endpoint of the study was freedom of AF after 12 months. Secondary endpoints were the following: acute AF termination, procedure time, fluoroscopy time and (post) procedural complications. Complications were divided into two categories: major and minor. Major complications were defined as: acute myocardial infarction, stroke, major bleeding and tamponade. Minor complications included: fever, pericarditis and inguinal haematoma.

Study population {#Sec3}
----------------

Only patients with LSP-AF, defined as AF being persistent for 12 months or longer, were included (Table [1](#Tab1){ref-type="table"}) \[[@CR17]\]. Exclusion criteria for this study were: fever or infection, renal failure (on dialysis or at risk of requiring dialysis, serum creatinine \>200 μmol/l), a malignancy needing therapy or a life expectancy shorter than the duration of the study. Additional exclusion criteria were intracardiac thrombus, severe cerebrovascular disease (neurological deficit of cerebrovascular cause that persists beyond 24 h), active gastrointestinal bleeding, bleeding or clotting disorders or inability to receive heparin and intractable heart failure (NYHA class IV).Table 1Patient demographics and procedural parametersDefragmentationNo defragmentation*P* valueNumber of patients (n)2017Age (years)59.2 ± 7.761.8 ± 6.8*p* = 0.28Male sex (n), (%)13 (65.0 %)15 (88.2 %)*p* = 0.10Years of AF (y)5.7 ± 6.15.6 ± 4.4*p* = 0.95Repeat procedures (n), (%)6 (30.0 %)2 (11.8 %)*p* = 0.17Class III antiarrhythmics (n), (%)13 (65.0 %)15 (88.2 %)*p* = 0.10Mean LA diameter (mm)47.4 ± 5.545.1 ± 4.9*p* = 0.21Left ventricular ejection fraction (%)47.8 ± 13.952.3 ± 13.1*p* = 0.66Mean procedure time (min)332.5 ± 78.3261.1 ± 96.6*p* = 0.02Mean fluoroscopy time (sec)58.3 ± 25.849.6 ± 20.8*p* = 0.33

Lastly, patients with an allergy to contrast, patients with uncontrolled diabetes (fasting blood glucose ≥10.0 mmol/l), pregnant patients or women of child-bearing potential not using a highly effective method of contraception and patients who were unable to attend the outpatients clinic were excluded from the study. The institutional ethics committee approved the study protocol and written informed consent was obtained from all patients.

Follow-up {#Sec4}
---------

All patients were followed up for 12 months. They attended outpatient appointments after 3, 6 and 12 months. An ECG was obtained at every visit. Before the procedure, a standard echo and a transoesophageal echo were performed. Data from the transthoracic echo was used to measure the left ventricular ejection fraction. Three months before and 12 months after the procedure, patients were fitted with a 24-hour ambulatory ECG device. The first month before and the third month after the procedure, patients received a transtelephonic cardiac event monitor, which they wore for 1 week. Every day patients submitted their ECG and were instructed to send extra recordings if they experienced any symptoms. After the first 3 months an assessment was made regarding the use for antiarrhythmic drugs (AADs). At 6 and 12 months after the procedure the need for anticoagulants was reassessed (Table [2](#Tab2){ref-type="table"}).Table 2Patient follow-up timelineBefore/after PVITimeActivity (ECG on every visit)Before3 months24-hour Holter registration1 monthTranstelephonic cardiac event monitor1 dayStandard echo, transoesophageal echo, standard blood workAfter3 monthsClinical visit, event recorder, AAD check up6 monthsClinical visit, assessment anticoagulants12 monthsAssessment anticoagulants, 24-hour Holter registration*AAD* antiarrhythmic drugs

### Treatment arms {#Sec5}

#### PVI with defragmentation {#d30e616}

All patients were treated with the Niobe Stereotaxis, Magnetic Navigation System (MNS) (Stereotaxis Inc., St. Louis MO, USA). The use of this system has been extensively described in previous reports \[[@CR18], [@CR19]\]. Every patient was treated under general anaesthesia because of the long procedure times and rather extensive and potentially painful ablation. Invasive arterial blood pressure monitoring was mandatory throughout the procedure. Pre-ablation 3D images (CT or MRI) were not routinely used as it was not considered essential for the procedures.

Both groins were prepared for puncture. Intracardiac echocardiography guided transseptal puncture was performed. Two 8.5 F SL1 (or SL0) sheaths were introduced into the left atrium. A decapolar catheter was placed into the coronary sinus. A Lasso catheter (Biosense Webster Inc., Diamond Bar, CA, USA) was inserted into the left atrium via one transseptal sheath. Using the second transseptal sheath a magnetic irrigated-tip mapping and ablation catheter (RMT Navistar, Biosense Webster Inc., Diamond Bar, CA, USA) was inserted in the left atrium.

The left atrium was extensively mapped (density: min 350 equally distributed points) using the MNS system. All PVs were mapped as separate chambers. Special attention was paid to the accurate definition of the PV ostia. The ablation sequence adhered to the following: First all PVs were isolated. Then electrogram-based ablation (i.e. defragmentation) in the left atrium and the coronary sinus was performed at all sites that displayed any of the following electrogram features: CFAEs, sites with a significant electrogram offset between distal and proximal recording bipoles of the mapping catheter suggesting a local re-entrant wavefront and regions with a cycle length (CL) shorter than the mean LA appendage CL. Specific CFAE maps using dedicated software were not performed.

Endpoint of ablation was in the transformation of fractionated electrograms into discrete electrograms and slowing of the mean atrial CL compared with LA appendage CL or the elimination of the electrograms in each region. If AF still persisted, linear ablation was performed: First a roof line, then a mitral line and lastly a posteroinferior line. The right atrium and superior vena cava were targeted for ablation if suspected to be a source perpetuating AF (lesser prolongation of CL in the right atrium, resulting in left-right fibrillatory CL gradient) and only after all LA ablation steps. Endpoint was the elimination or significant reduction (\>75 %) of the local electrograms along the ablation lines. After restoration of sinus rhythm, bidirectional block was assessed at every line using differential pacing methods. Arrhythmia induction was not part of this protocol. In case of conversion to a regular atrial tachycardia, this was targeted for ablation in the same session.

Power settings were conservatively and individually adjusted (note: these settings are valid only for ablation using the MNS). In all regions 25 W, 48°, and 30 s with an irrigation rate of 17 ml was used as initial setup. The bipolar and unipolar local electrograms were carefully and continuously monitored during and after every ablation application. If the local electrical activity persisted, the following adjustments were made: posterior wall: max 35 W, anterior wall: max 40 W, carina, or other ridge-like structures: max 45 W. At difficult regions ablation time was extended to 45 s. Thirty minutes after the last application all PVs were revisited to confirm electrical isolation.

#### PVI without defragmentation {#d30e635}

The same sequence as aforementioned was used, with the exception that after PVI and additional line ablation defragmentation was not performed.

Statistical analysis {#Sec6}
--------------------

The Kolmogorov-Smirnov test was used to assess the normality of distribution. Descriptive statistics was presented as mean ± SD for continuous variables if normally distributed. Continuous data were compared with the Student's *t* test or Mann-Whitney U test, where appropriate. Categorical data were presented as percentages and compared with the Fisher's exact test. Statistical analysis was performed with PASW version 18 (IBM Corp., Somers, NY). Statistical significance was defined as *P* \< 0.05 (two-tailed).

Results {#Sec7}
=======

Patient population {#Sec8}
------------------

A total of 37 patients were included. The defragmentation group had 20 patients and 17 patients were included in the non-defragmentation group. No differences in age, gender, years of AF, number of repeat procedure and use of class III antiarrhythmics were noted (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}). For the repeat procedures, a mean number of 1.75 ± 1.75 \[range 0--4\] PVs needed to be reisolated. The mean LA diameter of the whole population was 46.4 ± 5.3 mm. No difference in mean LA diameter was seen between the two groups (*P* = 0.214, Table [1](#Tab1){ref-type="table"}). Furthermore, there was no difference in left ventricular ejection fraction between the treatment arms (Table [1](#Tab1){ref-type="table"}). The mean number of electrical cardioversions in the whole population was 3.6 ± 3.0. No differences were seen between the defragmentation and the non-defragmentation group (3.2 ± 2.1 vs. 4.0 ± 3.7; *p* = 0.404, respectively).Table 3Use of antiarrhythmics before and after procedureDefragmentationNo DefragmentationAllBefore Amiodarone (n), %10 (50 %)13 (76.5 %)23 (62.2 %) Sotalol (n), %5 (25.0 %)6 (35.3 %)11 (29.7 %)After Amiodarone (n), %12 (63.2 %)12 (70.6 %)24 (66.7 %) Sotalol (n), %4 (21.1 %)3 (17.6 %)7 (19.4 %)

Ablation data {#Sec9}
-------------

Procedure times in the defragmentation group were longer and the use of fluoroscopy was comparable between both groups (Table [1](#Tab1){ref-type="table"}). The mean number of applications for the total group was 134.2 ± 69.6. A significant difference in the mean number of applications was seen between the defragmentation group and the non-defragmentation group (161.9 ± 74.1 vs. 96.5 ± 41.4, *P* = 0.014). Mean radiofrequency application time from the whole group was 3438 ± 1664 s. No difference in mean application time was reported between the defragmentation group and the non-defragmentation group (3947 ± 1782 vs. 2837 ± 1350 s, *P* = 0.105). Furthermore, no differences were observed between the two groups in acute AF termination (70.0 % vs. 76.5 %: *P* = 0.474).

Complications {#Sec10}
-------------

No major complications occurred in any of the patients. A significantly higher occurrence of minor complications was seen in the defragmentation group (45.0 % vs. 5.9 %, *P* = 0.009) (Fig. [1](#Fig1){ref-type="fig"}). No difference in type of minor complications was seen. Patients who experienced complications received a significantly higher number of radiofrequency (RF) applications (173.7 ± 69.9 vs. 109.6 ± 58.8, *P* = 0.019). Of all patients, 8.1 % (*n* = 3) had inguinal haematoma, 8.1 % (*n* = 3) had mild pericardial effusion, 5.4 % (*n* = 2) had fever and 2.7 % (*n* = 1) had pericardial effusion and fever. In the defragmentation group, 10.0 % (*n* = 2) had inguinal haematoma, 15.0 % (*n* = 3) had mild pericardial effusion, 10.0 % (*n* = 2) had fever and 5.0 % (*n* = 1) had mild pericardial effusion and fever. In the non-defragmentation group 1 (5.9 %) patient had inguinal haematoma. There was no difference in mean hospital stay between the defragmentation group and the non-defragmentation group (4.7 ± 2.2 vs. 3.4 ± 0.8, *P* = 0.06) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Percentage of minor complications for both the defragmentation and non-defragmentation groupFig. 2Average hospital stay presented with standard deviation for patients in the defragmentation and non-defragmentation group

Follow-up {#Sec11}
---------

For all three moments in time during follow-up (3, 6 and 12 months) no difference was observed in freedom of AF between the two groups (Fig. [3](#Fig3){ref-type="fig"}). After 3 months, 40.0 % of the patients in the defragmentation group were still in sinus rhythm, whereas in the non-defragmentation group this was 47.1 % (*P* = 0.611). At 6 months, the number of patients in sinus rhythm was 50.0 % vs. 35.3 % (*P* = 0.653). After completion of 12 months of follow-up 56.2 % of the patients from the defragmentation group were in sinus rhythm and 40.0 % of the patients in the non-defragmentation group (*P* = 0.344). During follow-up the use of AADs was comparable for the two groups (70.0 % vs. 76.5 %, *P* = 0.474) (Table [3](#Tab3){ref-type="table"}). In 13.5 % (*n* = 5) of the patients a repeat procedure was performed during follow. During electrophysiology (EP) study one patient had reconduction in both the left inferior and right superior PV, another in the right superior PV, another in the left superior PV, one patient had reconduction of all PVs and in one patient all PVs were isolated and additional defragmentation needed to be performed only. During follow-up, 24.3 % of the total population experienced atrial tachycardia. This was not statistically different when compared among the defragmentation and non-defragmentation group (11.8 % vs. 35.0 %, *P* = 0.103).Fig. 3The number of patients in sinus rhythm during follow-up. Data from three moments in time are presented (3, 6 and 12 months)

Discussion {#Sec12}
==========

This is the first study to evaluate the use of complete defragmentation using magnetic navigation in addition to conventional PVI and linear ablation. The major finding is that defragmentation for the ablation of LSP-AF after PVI and linear ablation is associated with a higher number of minor complications and more time-consuming procedures. After 12 months of follow-up no additional effect was observed for defragmentation therapy regarding freedom of AF. Therefore, the use of additional defragmentation for LSP-AF compromises procedural efficiency without improving efficacy.

Freedom of atrial fibrillation {#Sec13}
------------------------------

Achieving satisfactory success rates for ablation of LSP-AF is very challenging. As demonstrated by Brooks et al. \[[@CR4]\], a great variety of techniques remain available for the ablation of LSP-AF, including: PVI, pulmonary vein antrum isolation (PVAI) and different kinds of combinations of these treatments with ablation lines and defragmentation or CFAE ablation. Several other studies have evaluated the effect of the implementation of CFAE ablation for LSP-AF \[[@CR14], [@CR20], [@CR21]\]. The single-procedure, drug-free success rates from CFAE ablation alone range from 24 % to 33 % at approximately 1 year. However, no previous study has been performed on the use of subsequential PVI, linear ablation and defragmentation for LSP-AF and therefore makes it difficult to compare our results with previous findings.

Our study suggests that 56.2 % of the patients who had defragmentation are in sinus rhythm after 12 months of follow-up. However, most patients in the defragmentation and non-defragmentation group were on antiarrhythmic drugs during this period. Nevertheless, these patients suffered from severe drug-refractory AF prior to the ablation procedure. This may also explain the incremental increase in percentage of patients who were in sinus rhythm at 3, 6 and 12 months, respectively, after defragmentation therapy. In patients who underwent PVI and linear ablation without additional defragmentation, 40 % were free from AF. Since the difference between these groups did not meet statistical significance, it can be concluded that defragmentation therapy in addition to PVI and linear ablation does not improve outcome of LSP-AF.

Reconduction {#Sec14}
------------

One of the largest limitations of ablation for LSP-AF is the lack of durability of the venous electrical isolation \[[@CR22]\]. Prior studies demonstrated that the majority of patients had recovered venous conduction, which was established during the repeat procedure \[[@CR14], [@CR23], [@CR24]\]. This finding can be supported by our findings that a significant number of patients who experienced recurrence had PV reconduction during EP study. Willems et al. found PV reconduction in approximately 75 % of patients after the first procedure \[[@CR25]\]. For some patients with LSP-AF the PVs are an important trigger and durable lesions may improve outcome for these patients. Therefore, we cannot conclude that defragmentation therapy had no beneficial effect for patients with LSP-AF at all, since we are not yet able to perform ablations where durability of the PVI and linear ablations can be ensured over time. In this study a limited number of repeat procedures were performed and therefore we cannot draw conclusions about the specific cause of low success rates. Possibilities are reconduction after venous isolation, linear ablation, and insufficient defragmentation therapy. However, the single procedure success rate after 12 months is not improved by performing defragmentation in LSP-AF patients.

Amount of defragmentation {#Sec15}
-------------------------

Until today, the ideal amount of defragmentation for the treatment of LSP-AF remains unknown and is highly operator dependent. Our study demonstrates that additional defragmentation after linear ablation and PVI has no favourable effect on the outcome. A possible explanation for the ineffectiveness of defragmentation could be the amount of additional application time. Our results demonstrate that patients who underwent defragmentation received a significantly higher number of RF applications (on average 65 additional lesions). However, as the mean application time tends to be higher in the defragmentation group with approximately 1000 s of RF ablation, no statistically significant difference was found regarding total RF application time. The question rises as to whether more additional defragmentation would lead to an improved outcome. In other studies evaluating the effect of defragmentation in LSP-AF patients the average amount of additional RF application time was 15--33 min with a total application time of 54--64 min \[[@CR14], [@CR26]\]. Our study achieved comparable results regarding ablation data with 18.5 min additional defragmentation and a total ablation time of 66 min.

Complications {#Sec16}
-------------

Although we did not see a higher rate of major complications associated with defragmentation, as was the case in the study by Elayi and co-workers \[[@CR27]\], we observed a higher number of minor complications. Pericarditis due to extensive ablation remains a common complication \[[@CR28], [@CR29]\]. Our results demonstrated that patients who experienced any complications received significantly more RF applications (almost 70 more applications). This increased number of RF applications (\>200) is in some patients responsible for the occurrence of reactive pericarditis leading to mild pericardial effusion and fever. Most of the patients, however, recover spontaneously and are treated conservatively \[[@CR29]\]. Considering these complications and the fact that mean hospital stay and more importantly freedom of AF did not differ significantly according to our data could suggest that a certain restraint regarding the use of defragmentation may be indicated.

Clinical impact {#Sec17}
---------------

From the findings of this study, the question arises whether additional defragmentation may not be beneficial for all LSP-AF patients and should not be performed routinely, but for selected patients who did not benefit from PVI and linear ablation. In these individual patients the risk of persisting AF should be balanced against the risk associated with the procedure. However, as previously stated by Tilz et al. \[[@CR30]\], our study suggests that the additional risk of complication is not justifiable for an initial treatment with defragmentation.

When looking at the longer procedure times associated with defragmentation in our study (with a mean difference of almost 2 hours), one can conclude that ablation procedures could be much more efficient without this additional treatment and therefore less burdensome. This supports the findings concluded by Tilz et al. \[[@CR30]\] This might also influence the cost-efficacy of LSP-AF ablation procedures.

Limitations {#Sec18}
-----------

In this study a limited number of patients were included and analysed. However, despite this limited number of patients the absence of significant differences between the characteristics suggests homogeneity between the two groups and contributes to the validity of the conclusions drawn from these results. Furthermore, patient characteristics from our study population were in line with those from other studies \[[@CR4], [@CR14], [@CR27]\]. To really elucidate the effect of additional defragmentation in addition to conventional PVI and linear ablation randomised trials with a higher number of patients are necessary.

An important issue regarding follow-up which was raised by Tilz et al. \[[@CR30]\] remains whether observed AF recurrence rates merely depend on the length of follow-up. Like most studies about LSP-AF ablation, our follow-up lasted for 1 year and therefore does not offer further insight into this matter \[[@CR14], [@CR27]\]. However, longer follow-up would provide more detailed information on the treatment effect and the outcomes in the long term. In this study, patients were being treated with an antiarrhythmic drug during follow-up. Although the use of these drugs was comparable between the two groups, it might have influenced the outcomes during follow-up.

Conclusion {#Sec19}
==========

The lack of difference in freedom of AF and mean hospital stay between the two groups and the higher occurrence of minor complications in the defragmentation group suggests there is no strong ground to deliver complete defragmentation therapy in addition to PVI and linear ablation for patients suffering from LSP-AF.
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